Antiviral treatment and long-term clinical outcome of decompensated cirrhotic patients with hepatitis C virus infection
纪泛扑,党双锁,蔡芝芳,薛红安,黄娜,刘拉羊,张澍,郭永红,贾晓黎
DOI: https://doi.org/10.3760/cma.j.issn.1007-3418.2015.09.003
2015-01-01
Abstract:Objective To investigate the efficacy and safety of antiviral treatment in patients with hepatitis C virus (HCV) infection and decompensated cirrhosis and determine the effects of virological response on long-term prognosis.Methods Sixty-six consecutive,interferon (IFN)-na(i)ve patients with HCV infection and decompensated cirrhosis were enrolled in this prospective study.All patients were given a 48-to 72-week course of IFN plus ribavirin (RBV) combined therapy,with a low accelerating dosage regimen using either:pegylated (PEG)-IFNα-2b at 1.0-1.5 μg/kg/week,PEG-IFNα-2a at 90-180 μg,or standard IFN-α-2b at 3MU,every other day.RBV was given at 800-1000 mg/day.All patients were routinely monitored for adverse drug reactions and virological response.Effects of treatments on patient survival were assessed by Kaplan-Meier analysis.Results At the end of treatment,74.2％ of patients were HCV RNA-negative,with 45.5％ having achieved sustained virological response and 28.8％ having relapsed;the remaining 25.7％ of patients showed non-virological response (NVR).Among the patients with HCV genotype 1,65.9％ achieved end-of-treatment virological response (ETVR) and 34.1％ achieved SVR;among the patients with HCV genotype 2,90.9％ achieved ETVR and 68.2％ achieved SVR.The positive and negative predictive values of early virological response (EVR) for ETVR were 95.7％ and 75.0％ respectively,and for SVR were 65.2％ and 100％ respectively.Compared with baseline,patients who achieved ETVR had better liver function,as evidenced by changes in levels of total bilirubin,alanine aminotransferase and albumin,as well as prothrombin activity and Child-Pugh score (t =4.564,11.486,2.303,2.699,3.694 respectively,all P ＜ 0.05).Compared with the NVR patients,the ETVR patients had lower risk of hepatic decompensation and hepatocellular carcinoma,and had improved survival (x 2 =18.756,6.992,7.580,respectively,all P ＜ 0.05).Twelve (18.2％) patients experienced serious adverse events,with 10 requiring premature treatment withdrawal and 2 dying.Conclusion Antiviral treatment for patients with HCV infection and decompensated cirrhosis using interferon in a low accelerating dosage regimen in combination with ribavirin is feasible.Patients who achieved ETVR had significantly improved long-term prognosis.